Press Release

Turning Point Therapeutics to Sell to Bristol Myers Squibb for $4.1 Billion

June 3, 2022

San Diego – June 3, 2022 – Cooley is advising Turning Point Therapeutics, a leading precision oncology company, on its definitive agreement to be acquired by global biopharmaceutical company Bristol Myers Squibb. Lawyers Barbara Borden, Rowook Park, Charles Bair, Lindsey O’Crump, Vivian Tsai and Melissa Meza are leading the Cooley team advising Turning Point Therapeutics.

Under the agreement, Bristol Myers Squibb will commence a tender offer to acquire all the outstanding shares of Turning Point Therapeutics’ common stock at a price of $76.00 per share in an all-cash transaction, for a total consideration of $4.1 billion in equity value. The transaction is expected to close during the third quarter of 2022. 

“Through this transaction, we will be able to harness the full potential of our precision oncology platform to advance the standard of care for cancer patients,” Athena Countouriotis, MD, president and CEO of Turning Point Therapeutics, said in a press release. “With Bristol Myers Squibb’s leadership in oncology, strong commercial capabilities and manufacturing footprint, we will be able to further accelerate the pace at which we can bring our novel medicines to benefit people diagnosed with cancer around the world.”

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Turning Point Therapeutics’ pipeline of precision oncology drug candidates is being studied with a variety of solid tumors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 1,500 lawyers across 17 offices in the United States, Asia and Europe.


This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.